Genitourinary Cancer

Adjuvant pembrolizumab improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence.

The median radiologic progression-free survival was 12.02 months in the 177Lu-PSMA-617 group vs 5.59 months in the androgen receptor pathway inhibitor change group.

Nivolumab plus gemcitabine-cisplatin improved overall and progression-free survival in unresectable or metastatic urothelial carcinoma.

For the first time, a new therapeutic regimen outperformed chemotherapy in improving overall survival in frontline urothelial cancer.

Cancer screening tests may not extend life expectancy; however, they still are valuable for public health.

Older patients with kidney cancer experienced “exceptional” disease control with stereotactic ablative radiotherapy—which is noninvasive and occurs in the outpatient setting.

Clinical navigators helped increase the rate of genomic testing referrals among Black patients with prostate cancer—a group that faces significant health disparities in the care system.

Meredith Donahue, APRN-BC, discusses emerging therapies in metastatic prostate cancer.

The FDA has granted belzutifan priority review designation based on data from the phase 3 LITESPARK-005 trial.

The 2-year event-free survival rate among patients with muscle-invasive urothelial carcinoma was 75.7%.

Cabozantinib and atezolizumab led to a statistically significant progression-free survival improvement in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease.

The FDA has granted enzalutamide priority review designation based on data from the phase 3 EMBARK trial.

FoundationOne CDx is a next-generation sequencing–based in vitro diagnostic device developed to detect substitutions, insertion, and deletion alterations using 1 tissue sample.

Patients with nonmetastatic clinically node positive bladder cancer who wish to avoid major surgery may achieve similar clinical outcomes with trimodal therapy.

The phase 3 CheckMate-901 trial met its dual primary end points for progression-free survival and overall survival.

Patients with synchronous metastatic renal cell carcinoma experienced worse outcomes with first line immune-checkpoint inhibitors-based combinations vs those with metachronous disease.

Final overall survival analysis highlights benefit of lenvatinib plus pembrolizumab vs sunitinib in the treatment of patients with advanced renal cell carcinoma.

Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.

The onset of skeletal events and events that affect health-related quality of life were delayed with the addition of lutetium Lu 177 vipivotide tetraxetan to standard of care for patients with metastatic castration-resistant prostate cancer.

Among 32 patients, 66% experienced a prostate-specific antigen response rate of at least 50%.

The rate of pathologic complete responses with enfortumab vedotin was 36.4% among patients with muscle-invasive bladder.

A prostate stem cell antigen-directed CAR T-cell therapy agent showed preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Patients with advanced urothelial carcinoma who received avelumab reported any-grade treatment-related adverse events at a rate of 78.2%.

Talazoparib reduced the risk of progression or death by 55% in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Brenda Martone MSN, ANP-BC, AOCNP, discusses the safety data from the phase 3 ARASENS trial.

The PARP inhibitor talazoparib has been approved in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

The rates of treatment discontinuation were higher with enzalutamide and apalutamide than with darolutamide for patients with non-metastatic castration resistant prostate cancer.

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

A 5-year analysis of the phase 3 KEYNOTE-426 trial showed continued benefit with pembrolizumab plus axitinib for patients with advanced treatment-naïve clear cell renal cell carcinoma.